Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Finasteride is effective for treating male pattern baldness (MPB) with minimal side effects, and topical finasteride is similarly effective. Dutasteride is also effective but less understood, and Minoxidil is less effective than Finasteride.

Magnesium L-Threonate may help treat balding by reducing DKK-1 expression without affecting DHT. Users discuss its potential effectiveness and application methods, with some considering trying it topically.

A 20-year-old experiencing hair thinning is considering treatments like minoxidil, finasteride, and various oils but is hesitant due to potential side effects. Users advise starting minoxidil and finasteride for effective results, while oils and supplements are seen as less effective.

Apple core extract pills, believed to enhance hair density, are discussed as a potential treatment for hair loss. Users express cautious optimism and interest in trying the product, while acknowledging skepticism and the high cost.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

A user shared their experience obtaining a finasteride prescription through Lemonaid, highlighting the ease of the process without needing to provide photos. They chose oral finasteride for preventative hair loss treatment due to a family history of baldness and received a year’s supply at a low cost.

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

A 19-20-year-old has been using 0.5 mg of dutasteride daily for a year to combat hair loss, avoiding minoxidil due to side effects. They plan to continue this regimen and consider a future hair transplant, experiencing no significant side effects from dutasteride.

KX-826 shows promising results for hair growth with fewer side effects, offering an alternative to finasteride and minoxidil. Users discuss combining it with minoxidil, dermarolling, and Nizoral for improved results.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.

Finasteride and Dutasteride do not cause depression or mood disorders; hair loss itself may be a more significant factor. Some users experience side effects from Finasteride, but it is generally well-tolerated.

Hair loss is linked to a higher rate of body dysmorphic disorder (BDD), OCD, and depression. Finasteride and dutasteride are not linked to increased suicidal risk, though some users report mental health side effects.

The conversation humorously discusses hair loss treatments, focusing on finasteride, dutasteride, minoxidil, and microneedling. Users share experiences and opinions on the effectiveness and side effects of these treatments.

A 41-year-old South Asian individual feels hopeless about hair loss and cannot use oral finasteride or dutasteride due to existing gynecomastia. They are seeking advice on alternative treatments.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

Breezula offers modest hair growth similar to finasteride and is expected to be available by late 2026. It is a safe alternative without hormonal side effects and works well with minoxidil.

Bee venom at 0.001% concentration was more effective than 2% minoxidil in promoting hair growth in mice, possibly due to increased growth factors and reduced inflammation. Caution is advised due to potential allergic reactions and the reliance on animal data.

Hair loss is linked to DHT, with treatments like finasteride and minoxidil being common but not definitive. Economic interests influence research, and there is potential for new treatments like PP405 and RU58841.

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.

PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.

Minoxidil may inhibit androgen receptors and affect hormonal pathways, potentially explaining its effectiveness in treating androgenetic alopecia (AGA). Users discuss its varying effectiveness on scalp versus facial hair and note fewer side effects with topical use compared to oral.

New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

The conversation discusses hair loss treatments, with users sharing experiences and opinions on finasteride, minoxidil, and other methods. Many recommend finasteride for its effectiveness, while others express concerns about side effects and emphasize the importance of acting quickly to address hair loss.

People on finasteride or dutasteride cannot donate blood due to the risk of birth defects if the blood is given to a pregnant woman. It's advised to stop finasteride for a month and dutasteride for six months before donating.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

Procapil is marketed as a natural hair loss treatment but lacks strong evidence and is industry-biased. Minoxidil and Finasteride are the only FDA-approved treatments for androgenetic alopecia.

Dutasteride may not effectively stop scalp hair loss and can cause thinning of facial and body hair, including eyebrows. Users suggest considering other causes like autoimmune conditions or vitamin deficiencies and exploring treatments like finasteride or minoxidil.

A 38-year-old man is using topical and oral Minoxidil, DHT blocker shampoo, and microneedling for hair regrowth, with plans to add Finasteride later. Many users suggest starting Finasteride or Dutasteride immediately to address the root cause of hair loss, while some express concerns about potential side effects.

The user is experiencing significant hair loss after switching from finasteride to dutasteride for five months. Suggestions include that the hair loss might be a normal shedding phase, with some recommending continuing the treatment for up to 24 months or considering alternatives like RU58841.